UROGEN PHARMA LTD

URGNNASDAQ

🏆 #1993 by market capEarnings Nov 4US Equity

$40.50▼ $0.38 (−0.95%)

After hours · at close

🔔

Track URGN

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 0.9%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$1.97B

Small Cap

📈Revenue Growth (YoY)

+21.4%

Healthy

📊Gross Margin

90.8%

High

💵FCF Margin

-84.3%

Thin

⚖️P/S Ratio

10.7x

Elevated

Otter Score

Weak

No chart data available for URGN.

Trading Snapshot

Day Range: $39.93 – $40.74
52-Week Range: $15.86 – $50.81
Volume: $2.72B
Avg Volume: $2.62B
Shares Outstanding: 48.7M
Next Earnings: Oct 31, 2026

Fundamentals Snapshot

Annual Revenue: $110M
Last Q Revenue: $72M
P/E Ratio: -20.9
P/S Ratio: 10.7x
EPS (TTM): $-1.94
Dividend Yield: 0.00%
Dilution (1yr): +4.7%

Why Investors Own URGN

✓High-growth profile — revenue up +12.2% YoY with expanding US Equity exposure.
✓Healthy economics — 47% gross margin and 18% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

UROGEN PHARMA LTD

URGN

Financial Trends

Revenue

$110M▲ +21.4% YoY

Gross Margin

88.7%▼ −1.7% YoY

Operating Income

−$125M▲ +29.0% YoY

Free Cash Flow

−$163M▲ +67.7% YoY

Shares Outstanding

49.2M▲ +4.7% YoY

Net Cash

−$18M▼ −$66M YoY

StockOtter · stockotter.space

About UROGEN PHARMA LTD

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

🦦